NEU neuren pharmaceuticals limited

Ann: Annual Report 2019, page-2

  1. 33 Posts.
    lightbulb Created with Sketch. 113
    Very well presented and well written annual report. The Chairman’s address says it all. All value drivers remain the same. I have a feeling this annual report is considerably more a marketing document for the company than ever before. It’s obvious they will be targeting specific instos, and I expect the register will gradually change from retail to institutional over time (over the coming 6 to 12 months). I’m still not sure RE capital raising, but any discount would be minimal and the positive will be full steam ahead for phase 2 in 2591. I hope they announce progress soon on phase 1, even if it is just that they have commenced. I have a strong feeling that if we wind the clock forward 12 months we won’t recognise what we have today. Best of luck all.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.09
Change
0.240(1.87%)
Mkt cap ! $1.635B
Open High Low Value Volume
$13.15 $13.37 $12.92 $5.015M 382.2K

Buyers (Bids)

No. Vol. Price($)
7 286 $13.08
 

Sellers (Offers)

Price($) Vol. No.
$13.10 400 4
View Market Depth
Last trade - 13.36pm 18/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.